<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; win-win</title>
	<atom:link href="http://www.tapanray.in/tag/win-win/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Leverage Increased Focus On ‘Self-Care’ For Better Patient Outcomes</title>
		<link>http://www.tapanray.in/leverage-increased-focus-on-self-care-for-better-patient-outcomes/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=leverage-increased-focus-on-self-care-for-better-patient-outcomes</link>
		<comments>http://www.tapanray.in/leverage-increased-focus-on-self-care-for-better-patient-outcomes/#comments</comments>
		<pubDate>Mon, 24 Jan 2022 00:00:01 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[benefits]]></category>
		<category><![CDATA[C]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[infectious]]></category>
		<category><![CDATA[Leverage]]></category>
		<category><![CDATA[messaging]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[non-infectious]]></category>
		<category><![CDATA[normal]]></category>
		<category><![CDATA[Old]]></category>
		<category><![CDATA[opportunity]]></category>
		<category><![CDATA[ovid-19]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[self-care]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[win-win]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10640</guid>
		<description><![CDATA[‘People have been practicing self-care for thousands of years. Now an increase in self-care interventions is shifting the way health care is perceived, understood, and accessed, and adding to the many medicines, diagnostics, and technologies available for people to use &#8230; <a href="http://www.tapanray.in/leverage-increased-focus-on-self-care-for-better-patient-outcomes/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/leverage-increased-focus-on-self-care-for-better-patient-outcomes/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Focus On All 3 Areas of Innovation For Affordable Access To Innovative Drugs</title>
		<link>http://www.tapanray.in/focus-on-all-3-areas-of-innovation-for-affordable-access-to-innovative-drugs/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=focus-on-all-3-areas-of-innovation-for-affordable-access-to-innovative-drugs</link>
		<comments>http://www.tapanray.in/focus-on-all-3-areas-of-innovation-for-affordable-access-to-innovative-drugs/#comments</comments>
		<pubDate>Mon, 29 Nov 2021 00:00:53 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[ace]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[changing]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[differential]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[focus]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[Issues]]></category>
		<category><![CDATA[Models]]></category>
		<category><![CDATA[outcomesbusiness]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[problem]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[solution]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[three areas]]></category>
		<category><![CDATA[tiered]]></category>
		<category><![CDATA[win-win]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10615</guid>
		<description><![CDATA[Medical treatment has made astonishing advances over the years. But the packaging and delivery of that treatment are often inefficient, ineffective, and consumer unfriendly. This was articulated in an article on innovation in healthcare, published in the Harvard Business Review, way &#8230; <a href="http://www.tapanray.in/focus-on-all-3-areas-of-innovation-for-affordable-access-to-innovative-drugs/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/focus-on-all-3-areas-of-innovation-for-affordable-access-to-innovative-drugs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Creative Pharma Marketers To Unshackle Covid Fetters</title>
		<link>http://www.tapanray.in/creative-pharma-marketers-to-unshackle-covid-fetters/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=creative-pharma-marketers-to-unshackle-covid-fetters</link>
		<comments>http://www.tapanray.in/creative-pharma-marketers-to-unshackle-covid-fetters/#comments</comments>
		<pubDate>Mon, 09 Nov 2020 00:00:55 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[clinic]]></category>
		<category><![CDATA[colossal]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[creative]]></category>
		<category><![CDATA[doctor]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Fetters]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[in-person]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[limitations]]></category>
		<category><![CDATA[marketers]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[overcome]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[physicians]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reality]]></category>
		<category><![CDATA[strategies]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[task]]></category>
		<category><![CDATA[Telehealth]]></category>
		<category><![CDATA[telemedicine]]></category>
		<category><![CDATA[Unshackle]]></category>
		<category><![CDATA[visits]]></category>
		<category><![CDATA[win-win]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10317</guid>
		<description><![CDATA[Pharma industry, just as most others, has started recognizing that the business needs to be brought back to normal, despite Covid fetters. Some early evidences suggest, a new breed of pharma marketers is refusing to get confined to Covid triggered &#8230; <a href="http://www.tapanray.in/creative-pharma-marketers-to-unshackle-covid-fetters/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/creative-pharma-marketers-to-unshackle-covid-fetters/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A New Pharma Marketing Combo Places Patients At The Center Of Business</title>
		<link>http://www.tapanray.in/a-new-pharma-marketing-combo-places-patients-at-the-center-of-business/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=a-new-pharma-marketing-combo-places-patients-at-the-center-of-business</link>
		<comments>http://www.tapanray.in/a-new-pharma-marketing-combo-places-patients-at-the-center-of-business/#comments</comments>
		<pubDate>Mon, 01 Apr 2019 00:00:30 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[analytics]]></category>
		<category><![CDATA[behavioral]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[centric]]></category>
		<category><![CDATA[centricity]]></category>
		<category><![CDATA[combo]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[marketers]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[organization]]></category>
		<category><![CDATA[outcome]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[performance]]></category>
		<category><![CDATA[predictive]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[science]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[win-win]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9464</guid>
		<description><![CDATA[As discussed in several of my previous articles, most pharma players need to walk the talk on ‘patient-centricity&#8217;, coming out of prevailing high decibel lip-service. This is not an easy task, and far from being every company’s cup of tea. Effective &#8230; <a href="http://www.tapanray.in/a-new-pharma-marketing-combo-places-patients-at-the-center-of-business/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/a-new-pharma-marketing-combo-places-patients-at-the-center-of-business/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>More Glivec Like Deals in China and Mounting Global Challenges: Innovators poised Joining Biosimilar Bandwagon</title>
		<link>http://www.tapanray.in/more-glivec-like-deals-in-china-and-mounting-global-challenges-innovators-poised-joining-biosimilar-bandwagon/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=more-glivec-like-deals-in-china-and-mounting-global-challenges-innovators-poised-joining-biosimilar-bandwagon</link>
		<comments>http://www.tapanray.in/more-glivec-like-deals-in-china-and-mounting-global-challenges-innovators-poised-joining-biosimilar-bandwagon/#comments</comments>
		<pubDate>Mon, 15 Apr 2013 00:00:04 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[12years]]></category>
		<category><![CDATA[AbVie]]></category>
		<category><![CDATA[advantage]]></category>
		<category><![CDATA[Amgen]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[bandwagon]]></category>
		<category><![CDATA[Barriers]]></category>
		<category><![CDATA[biologics]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Cipla]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[development]]></category>
		<category><![CDATA[drivers]]></category>
		<category><![CDATA[DRL]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[EliLilly]]></category>
		<category><![CDATA[entry]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[Genentech]]></category>
		<category><![CDATA[Glivec]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Herceptin]]></category>
		<category><![CDATA[Hospira]]></category>
		<category><![CDATA[Humira]]></category>
		<category><![CDATA[IMS]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Innovators]]></category>
		<category><![CDATA[J&J]]></category>
		<category><![CDATA[joining]]></category>
		<category><![CDATA[LG]]></category>
		<category><![CDATA[low]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[products]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Remicade]]></category>
		<category><![CDATA[Rituxan]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Teva]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USA]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[win-win]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2164</guid>
		<description><![CDATA[Pressure from the emerging markets on pricing of patented products is mounting fast. This time the country involved is China. Recently, the Health Minister of China who stepped down last month after a seven-year stint in the top health job &#8230; <a href="http://www.tapanray.in/more-glivec-like-deals-in-china-and-mounting-global-challenges-innovators-poised-joining-biosimilar-bandwagon/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/more-glivec-like-deals-in-china-and-mounting-global-challenges-innovators-poised-joining-biosimilar-bandwagon/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
